AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...

CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), has signed a national agreement with ...

Investing.com -- Plus Therapeutics Inc (NASDAQ:PSTV) stock surged 60% in premarket trading Thursday after the company ...

Controlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024 AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus ...

Plus Therapeutics Inc. (NASDAQ:PSTV) jumped 60% in premarket trading Thursday following news of a national agreement with ...

The test supports rapid diagnosis, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.

This content has been selected, created and edited by the Finextra editorial team based upon its relevance and interest to our community. Better known as brute force attack, an enumeration attack ...